In this section
The publication feed below is often incomplete and out of date; for an up to date summary of our publications please see Google Scholar or Pub Med
@article{Serwa:2011:10.1016/j.chembiol.2011.04.002,
author = {Serwa, R and Tate, EW},
doi = {10.1016/j.chembiol.2011.04.002},
journal = {Chemistry and Biology},
pages = {407--409},
title = {Activity-based profiling for drug discovery},
url = {http://dx.doi.org/10.1016/j.chembiol.2011.04.002},
volume = {18},
year = {2011}
}
TY - JOUR
AB - Activity-based protein profiling (ABPP) is emerging as a game-changing tool for drug discovery, target validation, and basic biology. In this issue, Chang et al. (2011) report the ABPP-facilitated discovery of JW480, a highly selective potent and orally bioavailable inhibitor of monoalkylglycerol ether hydrolase KIAA1363 that dramatically impairs in vivo growth of human prostate cancer cell lines.
AU - Serwa,R
AU - Tate,EW
DO - 10.1016/j.chembiol.2011.04.002
EP - 409
PY - 2011///
SN - 1879-1301
SP - 407
TI - Activity-based profiling for drug discovery
T2 - Chemistry and Biology
UR - http://dx.doi.org/10.1016/j.chembiol.2011.04.002
UR - http://hdl.handle.net/10044/1/26862
VL - 18
ER -
Prof. Ed Tate
GSK Chair in Chemical Biology
Department of Chemistry
Molecular Sciences Research Hub, White City Campus,
82 Wood Lane, London, W12 0BZ
e.tate@imperial.ac.uk
Tel: +44 (0)20 759 + ext 43752 or 45821